T F Jakobs1, K J Paprottka2, F Raeßler2, F Strobl2, S Lehner3, H Ilhan3, C G Trumm2, W P Fendler3, W Sommer2, P M Paprottka2. 1. Department of Diagnostic and Interventional Radiology, Barmherzige Brueder Munich, Romanstraße 93, 80639, Munich, Germany. tobias.jakobs@barmherzige-muenchen.de. 2. Department of Clinical Radiology, LMU - University of Munich, Munich, Germany. 3. Department of Nuclear Medicine, LMU - University of Munich, Munich, Germany.
Abstract
OBJECTIVES: Our aim was to provide further evidence for the efficacy/safety of radioembolization using yttrium-90-resin microspheres for unresectable chemorefractory liver metastases from colorectal cancer (mCRC). METHODS: We followed 104 consecutively treated patients until death. Overall survival (OS) was calculated from the day of the first radioembolization procedure. Response was defined by changes in tumour volume as defined by Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 and/or a ≥30 % reduction in serum carcinoembryonic antigen (CEA) at 3 months. RESULTS: Survival varied between 23 months in patients who had a complete response to prior chemotherapy and 13 months in patients with a partial response or stable disease. Median OS also significantly improved (from 5.8 months to 17.1 months) if response durability to radioembolization extended beyond 6 months. Patients with a positive trend in CEA serum levels (≥30 % reduction) at 3 months post-radioembolization also had a survival advantage compared with those who did not: 15.0 vs 6.7 months. Radioembolization was well tolerated. Grade 3 increases in bilirubin were reported in 5.0 % of patients at 3 months postprocedure. CONCLUSIONS: After multiple chemotherapies, many patients still have a good performance status and are eligible for radioembolization. This single procedure can achieve meaningful survivals and is generally well tolerated. KEY POINTS: • After multiple chemotherapies, many patients are still eligible for radioembolization (RE). • RE can achieve meaningful survival in patients with chemorefractory liver-predominant metastatic colorectal cancer (mCRC). • Tumour responsiveness to prior systemic treatments is a significant determinant of overall survival (OS) after RE. • Radioembolization in patients with a good performance status is generally well tolerated.
OBJECTIVES: Our aim was to provide further evidence for the efficacy/safety of radioembolization using yttrium-90-resin microspheres for unresectable chemorefractory liver metastases from colorectal cancer (mCRC). METHODS: We followed 104 consecutively treated patients until death. Overall survival (OS) was calculated from the day of the first radioembolization procedure. Response was defined by changes in tumour volume as defined by Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 and/or a ≥30 % reduction in serum carcinoembryonic antigen (CEA) at 3 months. RESULTS: Survival varied between 23 months in patients who had a complete response to prior chemotherapy and 13 months in patients with a partial response or stable disease. Median OS also significantly improved (from 5.8 months to 17.1 months) if response durability to radioembolization extended beyond 6 months. Patients with a positive trend in CEA serum levels (≥30 % reduction) at 3 months post-radioembolization also had a survival advantage compared with those who did not: 15.0 vs 6.7 months. Radioembolization was well tolerated. Grade 3 increases in bilirubin were reported in 5.0 % of patients at 3 months postprocedure. CONCLUSIONS: After multiple chemotherapies, many patients still have a good performance status and are eligible for radioembolization. This single procedure can achieve meaningful survivals and is generally well tolerated. KEY POINTS: • After multiple chemotherapies, many patients are still eligible for radioembolization (RE). • RE can achieve meaningful survival in patients with chemorefractory liver-predominant metastatic colorectal cancer (mCRC). • Tumour responsiveness to prior systemic treatments is a significant determinant of overall survival (OS) after RE. • Radioembolization in patients with a good performance status is generally well tolerated.
Authors: Andrew S Kennedy; David Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Steven C Rose; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang Journal: J Gastrointest Oncol Date: 2015-04
Authors: Hamid Chalian; Hüseyin Gürkan Töre; Jeanne M Horowitz; Riad Salem; Frank H Miller; Vahid Yaghmai Journal: Radiographics Date: 2011 Nov-Dec Impact factor: 5.333
Authors: Guy Van Hazel; Anthony Blackwell; James Anderson; David Price; Paul Moroz; Geoff Bower; Giuseppe Cardaci; Bruce Gray Journal: J Surg Oncol Date: 2004-11-01 Impact factor: 3.454
Authors: David M Liu; Avnesh S Thakor; Mark Baerlocher; Mohammed T Alshammari; Howard Lim; Sebastian Kos; Andrew S Kennedy; Harpreet Wasan Journal: Future Oncol Date: 2015-01-20 Impact factor: 3.404
Authors: M Stutz; A Mamo; D Valenti; A Hausvater; T Cabrera; P Metrakos; P Chaudhury; G Steacy; E Garoufalis; P Kavan Journal: Gastroenterol Res Pract Date: 2015-02-26 Impact factor: 2.260
Authors: K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-14 Impact factor: 9.236
Authors: Frederic Carsten Schmeel; Birgit Simon; Julian Alexander Luetkens; Frank Träber; Carsten Meyer; Leonard Christopher Schmeel; Amir Sabet; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh Journal: J Cancer Res Clin Oncol Date: 2017-03-19 Impact factor: 4.553
Authors: Nikhil Chauhan; Mary F Mulcahy; Riad Salem; Al B Benson Iii; Eveline Boucher; Janet Bukovcan; David Cosgrove; Chantal Laframboise; Robert J Lewandowski; Fayaz Master; Bassel El-Rayes; Jonathan R Strosberg; Daniel Y Sze; Ricky A Sharma Journal: JMIR Res Protoc Date: 2019-01-17